As patient survival drops precipitously from early-stage cancers to late-stage and metastatic cancers, microRNAs that promote relapse and metastasis can serve as prognostic and predictive markers as well as therapeutic targets for chemoprevention. Here we show that miR-1269a promotes colorectal cancer (CRC) metastasis and forms a positive feedback loop with TGF-β signalling. miR-1269a is upregulated in late-stage CRCs, and long-term monitoring of 100 stage II CRC patients revealed that miR-1269a expression in their surgically removed primary tumours is strongly associated with risk of CRC relapse and metastasis. Consistent with clinical observations, miR-1269a significantly increases the ability of CRC cells to invade and metastasize in vivo. TGF-β activates miR-1269 via Sox4, while miR-1269a enhances TGF-β signalling by targeting Smad7 and HOXD10, hence forming a positive feedback loop. Our findings suggest that miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a potential therapeutic target to deter metastasis.
Many solid tumours progress through stages while accumulating genetic alterations and reprogramming microenvironments1,2. Ranked among the most common cancers and a leading cause of cancer-related deaths3,4, colorectal cancer (CRC) progresses through an adenomas to carcinoma sequence that eventually leads to metastasis5,6. The stage of CRC is specified by the American Joint Committee on Cancer (AJCC) tumour-node-metastasis staging system, which provides the guideline for treatment. Stages I and II are usually considered non-invasive, stage III has spread to lymph nodes and stage IV involves metastasis. However, although there is consensus to treat stage I CRC with only surgery and stages III/IV CRC with chemotherapy in addition to surgery, the overall benefit of adjuvant chemotherapy after resection of stage II CRC remains unclear7. Still, chemotherapy likely improves survival for certain subsets of stage II patients. As patient survival drops from 80 to 90% for early-stage CRCs to below 10% for late-stage and metastatic CRCs, it is important to identify prognostic markers and therapeutic targets for chemoprevention8.
microRNAs are small noncoding RNA molecules that suppress gene expression via the 3′ untranslated regions (UTRs) of target mRNAs. Individual microRNA can control many target genes and microRNA expression is often altered in cancer cells9. Among them, microRNAs that promote relapse and metastasis are of particular interest as potential prognostic biomarkers and therapeutic targets10,11.
In this study, we show that miR-1269a expression is upregulated in late-stage CRC and is associated with recurrence and metastasis of disease-free stage II CRC patients. miR-1269a promotes CRC cells to undergo epithelial–mesenchymal transition (EMT) and to metastasize in vivo. Mechanistically, miR-1269 targets Smad7 and HOXD10 to enhance transforming growth factor (TGF)-β signalling, which in turn upregulates miR-1269 via Sox4.
miR-1269 is upregulated in late-stage CRC tumours
To investigate the roles of microRNAs in CRC progression, we systematically compared microRNA expression levels in early- versus late-stage CRC tumours using the latest COlon ADenocarcinoma (COAD) miRNASeq data set in The Cancer Genome Atlas (TCGA)12 (see Methods). Differential expression analysis based on read counts identified miR-1269 as a top microRNA candidate that is upregulated in stage IV CRCs versus stage I and II CRCs, with a P-value of 0.01 (Fig. 1a–c and Supplementary Fig. 1, Supplementary Table 1). We did not include Stage III CRCs in our TCGA analysis because their metastatic potential was less clear and may vary widely between individuals.
The miR-1269 family has two isoforms, miR-1269a and miR-1269b. To validate the TCGA analysis, we measured miR-1269a and miR-1269b expression levels in 12 early-stage and 17 late-stage CRC tumours acquired from the Weill Cornell Medical College (WCMC) Colon Cancer Biobank (Supplementary Table 2). Late-stage CRCs have higher miR-1269a expression levels than early-stage CRCs in a statistically significant manner according to reverse transcription–quantitative PCR (RT–qPCR) measurements, consistent with the TCGA finding (Fig. 1d). On the other hand, miR-1269b level was not statistically different between early- and late-stage CRC samples.
miR-1269 is a marker for CRC relapse and metastasis
Generally, it is difficult to predict whether stage II CRC patients will relapse or develop metastasis after surgical removal of their primary tumours, although 10–20% of stage II patients will eventually relapse. To explore whether miR-1269a is a prognostic marker for relapse and metastasis, we performed a clinical study on 100 stage II CRC patients at the Catalan Institute of Oncology (Tables 1 and 2)13. These disease-free patients were considered ‘low-risk’ for relapse and did not undergo chemotherapy after the surgery. The patients were divided into two cohorts, ‘miR-1269alow’ and ‘miR-1269ahigh’, based on the miR-1269a expression levels measured in their surgically removed primary tumours. Based on risk of relapse for stage II CRC, we allocated the top 10% (10 patients) into the miR-1269ahigh cohort and the rest (90 patients) into the miR-1269alow cohort to see whether miR-1269a expression could distinguish the small subset of patients who actually had high risk of relapse.
Follow-up revealed that high miR-1269a expression was associated with relapse and metastasis of these disease-free patients (logrank P=0.002). The miR-1269ahigh cohort had a significantly higher recurrence rate than the miR-1269alow cohort, based on disease-free survival curves from Kaplan–Meier analysis (Fig. 1e). Distant metastasis developed in only 18% of the patients in the miR-1269alow cohort, but in 60% of the patients in the miR-1269ahigh cohort (Table 1). The prognostic value of miR-1269a for disease-free survival was significant (P=0.015) in a multivariable Cox’ proportional hazards model adjusted for age, sex, subsite (left/right) and sub-stage (IIa/IIb; Table 2). These results indicate that miR-1269a could be a potential marker associated with a small subset of high-risk CRC Stage II patients who were previously deemed low-risk and may benefit from chemotherapy after surgery. We also explored cut points of miR-1269a expression that stratified patients at 15 and 20 upper percentiles, and the miR-1269ahigh cohort still had higher recurrence rate than the miR-1269alow cohort in a statistically significant way (P=0.009 and 0.022). Similar analysis on miR-1269b showed that miR-1269b was not associated with risk of relapse (Supplementary Fig. 2a).
miR-1269a expression in CRC cell lines
We measured miR-1269a expression in six commonly used CRC cell lines (Fig. 1f). In general, miR-1269a levels are low in cells with relatively low metastatic potential (HT29 and SW480), and are high in cells with relatively high metastatic potential (DLD1, LoVo, LS174T and SW620). One ambivalent case is the low miR-1269a expression in HCT116 cells, which were derived from primary adenocarcinoma but seem to possess metastatic potential. It is likely that HCT116 cells have accumulated other metastasis-promoting mutations. Notably, the miR-1269a level is sixfold higher in SW620 cells than in SW480 cells. Originally from the same CRC patient, SW480 was derived from a primary colon adenocarcinoma before relapse, whereas SW620 was derived from mesenteric lymph nodes metastases post-relapse14. Hence, this controlled comparison between the two patient-matched cell lines supported that miR-1269a levels are associated with metastatic potential. Unlike miR-1269a, miR-1269b exhibited similar expression levels in SW480 and SW620 cells (Supplementary Fig. 2b). Therefore, we decided to focus on miR-1269a for the rest of the study.
miR-1269a promotes CRC metastasis
To evaluate the effect of miR-1269a on SW480 cells, which have low endogenous miR-1269a expression, we ectopically expressed miR-1269a in SW480 cells. Ectopic miR-1269a only slightly increased cell growth in vitro (Supplementary Fig. 3) and subcutaneous xenograft tumour growth in vivo (Fig. 2a). However, Transwell migration assay (Fig. 2b) and Matrigel invasion assay (Fig. 2c) showed that ectopic expression of miR-1269a increased migration and invasion of SW480 cells significantly.
To investigate whether miR-1269a promotes metastasis in vivo, we used an established CRC orthotopic model by implanting human CRC cells into cecum terminus of NOD/SCID mice15,16. SW480 cells were infected with lentiviral vectors to establish two stable lines that either expressed miR-1269a (SW480-miR-1269a) or contained a control vector (SW480-NC). These cells also carry constitutive luciferase and mCherry reporter constructs. After cecal implantation of equal numbers of cells from both lines, metastasis was tracked using the whole-body IVIS bioluminescence imaging system. Once a mouse became moribund, all mice were killed simultaneously and hepatic metastases expressing mCherry were analysed by imaging the entire liver with a fluorescent microscope. SW480-NC cells failed to metastasize to liver in all 8 mice (0/8). In contrast, 7 out 8 (7/8) mice injected with SW480-miR-1269a cells developed hepatic metastases (Fig. 2d,e,f,j and Supplementary Fig. 4a,b). Hence, ectopic miR-1269a expression promotes metastasis of SW480 cells in vivo.
To investigate whether silencing of miR-1269a expression in metastatic cells impedes their ability to metastasize, we knocked down endogenous miR-1269a levels in SW620 cells, the metastatic counterpart of SW480 from the same patient. SW620 cells were infected with lentiviral vectors to establish two stable lines that either expressed antisense RNA against miR-1269a (SW620-Anti-miR-1269a) or contained a control vector (SW620-Anti-NC). The mir-1269a knockdown efficiency in SW620-Anti-miR-1269a cells was evaluated by a luciferase reporter (Supplementary Fig. 5). Equal numbers of SW620-Anti-NC and SW620-Anti-miR-1269a cells were implanted into the ceca of NOD/SCID mice. All mice were simultaneously killed for metastasis examination when one became moribund. Six out of eight (6/8) mice injected with SW620-Anti-NC cells developed hepatic metastases, whereas only 1 out of 8 (1/8) mice injected with SW620-Anti-miR-1269a cells developed hepatic metastasis (Fig. 2g,h,i,k and Supplementary Fig. 4c,d). Thus, miR-1269a knockdown suppressed metastasis of SW620 cells in vivo.
In addition to the cecum-injection model, we performed intravenous injection through tail vein with the same cells. In the group injected with SW480-miR-1269 cells, all 10 mice developed lung metastasis, with a large number of metastatic nodules covering the entire lung. In contrast, only 4 out of 10 mice injected with SW480-NC cells developed lung metastasis, with a small number of metastatic nodules (Supplementary Fig. 6a–c). miR-1269a also promoted CRC colonization of the liver. Only 1 out of the 10 mice injected with SW480-NC cells developed liver metastasis, whereas 5 out of the 10 mice injected SW480-miR-1269a cells developed liver metastasis (Supplementary Fig. 6d-f). Consistent with SW480 cells, ectopic miR-1269a expression in HCT116 also enhanced lung and liver metastasis, compared with the control vector (Supplementary Fig. 6g,h). Therefore, miR-1269a expression promoted colonization of circulating SW480 and HCT116 cells in the lung and the liver.
Similarly, equal numbers of SW620-Anti-NC and SW620-Anti-miR-1269a were intravenously injected through tail vein. In the control group (SW620-Anti-NC), all 10 mice (10/10) developed lung metastasis and 4 out of 10 (4/10) developed liver metastasis, which is consistent with the high metastatic potential of SW620. miR-1269a knockdown significantly reduced lung and liver metastasis of SW620 cells. In the SW620-Anti-miR-1269a group, only 3 out 10 (3/10) mice developed lung metastasis and 1 out 10 (1/10) developed liver metastasis (Supplementary Fig. 6a–f). The SW620 data were further corroborated by knocking down miR-1269a in LS174T cells, which also have high endogenous miR-1269a expression. Injected LS174T control cells formed extensive metastasis in the lung, lymph nodes in the lateral thoracic region and the bone. In contrast, miR-1269a knockdown in LS174T cells significantly reduced metastasis in these regions (Supplementary Fig. 6i). Therefore, silencing of endogenous miR-1269a mitigated colonization of circulating SW620 and LS174T cells.
Collectively, the in vitro migration and invasion assays and in vivo metastasis assays, with ectopic expression of miR-1269a in SW480 and HCT116 cells and knockdown of endogenous miR-1269a in SW620 and LS174T cells, indicate that miR-1269a promotes CRC metastasis.
miR-1269a promotes an EMT-like process
As an EMT-like process has been associated with colon cancer metastasis17, we examined whether miR-1269a promotes EMT. We measured the levels of the epithelial marker E-cadherin and the mesenchymal markers N-cadherin and Vimentin in SW480-miR-1269a and SW480-NC cells using both western blot analysis and immunofluorescence. Compared with the control SW480-NC cells, which had high E-cadherin expression and low N-cadherin and Vimentin expression, SW480-miR-1269a cells had significantly downregulated E-cadherin expression and upregulated N-cadherin and Vimentin expression (Fig. 3a,b). Consistent with the EMT markers, SW480-miR-1269a cells adopted a spindle-shaped, mesenchymal-like morphology in contrast to the epithelial-like morphology of SW480-NC cells (Fig. 3c). Hence ectopic miR-1269a expression causes SW480 cells to undergo EMT.
We then examined whether silencing of miR-1269a could impede the ability of cells to undergo EMT. As the metastatic counterpart of SW480, SW620 cells have higher endogenous miR-1269a expression levels than SW480 cells. miR-1269a knockdown reduced N-cadherin and Vimentin levels in SW620 cells, as shown by immunofluorescence and western blot (Fig. 3d,e). TGF-β1 treatment turned on N-cadherin and Vimentin expression and turned down E-cadherin expression in the control (SW620-Anti-NC) cells, which started to display a mesenchymal-like morphology (Fig. 3f). In contrast, the effect of TGF-β1 induction was much attenuated by miR-1269a knockdown, as SW620-Anti-miR-1269a cells largely maintained E-cadherin expression and the epithelial-like morphology in the presence of TGF-β1 (Fig. 3d–f). Therefore, miR-1269a knockdown impedes the ability of SW620 cells to undergo an EMT-like process upon TGF-β induction. Together, the data indicate that miR-1269a not only promotes an EMT-like process, but is also involved with TGF-β-induced transformation of CRC cells.
TGF-β activates miR-1269a via Sox4
To explore the crosstalk between miR-1269a and TGF-β, we treated SW480 cells with TGF-β1 and measured the response of miR-1269a by RT–qPCR. TGF-β1 treatment upregulated miR-1269a expression, suggesting that TGF-β is an upstream regulator of miR-1269a (Fig. 4a). Genomic analysis identified two Sox4-binding motifs at −173 to −166 (site 1) and −947 to −940 (site 2) inside the putative miR-169 promoter region (Fig. 4b). Notably, Sox4 is a downstream target gene of TGF-β18 and has been reported to be a master regulator of EMT and cancer metastasis19. Therefore, Sox4 is a potential intermediate between TGF-β and miR-1269a. Notably, Sox4 expression level was higher in SW620 cells than in SW480 cells, similar to miR-1269 (Supplementary Fig. 7).
We then tested whether Sox4 can activate the miR-1269a promoter as suggested by their binding motifs. In SW480 cells, ectopic expression of Sox4 caused a fourfold increase of miR-1269a expression level, compared with cells transfected with a control vector (Fig. 4c). We then tested whether Sox4 is the intermediate regulator that is required for TGF-β-induced miR-1269a upregulation. Compared with the control cells, Sox4 knockdown by short hairpin RNA (shSox4) completely abolished the effect of TGF-β1 on miR-1269a expression, consistent with Sox4 as an intermediate regulator between TGF-β1 and miR-1269a (Fig. 4d).
To address whether Sox4 directly activates miR-1269a expression, we performed chromatin immunoprecipitation (ChIP) assays in SW480 and HT29 cells. ChIP confirmed that Sox4 proteins were recruited to both binding sites in the putative miR-1269a promoter, with the majority of Sox4 bound to site 1 (Fig. 4e, f). To test whether the binding of Sox4 is sufficient to activate miR-1269a expression, we cloned the putative miR-1269a promoter sequence into a pGL4-basic vector, which were subsequently transfected into SW480 and HT29 cells. A dual-luciferase reporter assay revealed that ectopic expression of Sox4 activated the transcription of firefly luciferase that was driven by the wild-type miR-1269a promoter. When the binding sequence of site 1 was mutated, firefly luciferase expression dropped 6.8-fold in SW480 cells and 5.4-fold in HT29. When the binding sequence of site 2 was mutated, firefly luciferase expression dropped 4.6-fold in SW480 and 5.7-fold in HT29 (Fig. 4g, h). Therefore, Sox4 directly binds to these two sites to activate miR-1269a expression.
We then examined whether endogenous Sox4 binding to the miR-1269 promoter increases upon TGF-β induction. We treated SW480 cells with TGF-β1 and then performed ChIP. As expected, more Sox4 proteins were recruited to both binding sites in the miR-1269 promoter after TGF-β1 treatment (Fig. 4i). Next, to investigate whether Sox4 promotes in vivo metastasis as miR-1269 does, we ectopically expressed Sox4 in SW480 cells and implanted them into mouse ceca. Consistent with ectopic miR-1269 expression, ectopic Sox4 expression significantly enhanced SW480 hepatic metastasis (Fig. 4j,k).
Taken together, our data indicate that TGF-β upregulates miR-1269a through Sox4, which binds to the two Sox4-binding sites in the miR-1269a promoter to activate miR-1269a expression. Thus, TGF-β, Sox4 and miR-1269a act synergistically to promote EMT and metastasis.
miR-1269a targets Smad7 and HOXD10
To determine miR-1269a target genes, we searched for computationally predicted candidates using miRecords, which compiles 11 microRNA targets prediction databases such as PicTar, miRanda, TargetScan and RNA hybrid (Supplementary Table 3). We then used RT–qPCR to compare expression levels of the candidate genes between ectopic miR-1269a expression and control in SW480 and HT29 cells. Among the candidates, homeobox D10 (HOXD10) has been reported to suppress tumour invasion and metastasis20, whereas Smad7 is a well-known antagonist of TGF-β signalling21. Smad7 and HOXD10 were downregulated in both SW480 and HT29 cells by miR-1269a (Fig. 5a,b). Western blot confirmed that miR-1269a suppresses Smad 7 and HOXD10 protein levels (Fig. 5c,d).
To test whether they are direct targets of miR-1269a, the 3′UTRs of the two genes were cloned downstream of firefly luciferase. The luciferase reporters were then co-transfected with a miR-1269a-expressing construct or an empty control vector into SW480 cells. Cells with ectopic miR-1269a expression had suppressed Smad7 and HOXD10 levels, in contrast to the control cells, whereas mutation in the putative miR-1269a seed regions in the 3′UTRs of either Smad7 or HOXD10 abrogated the suppression of miR-1269a (Fig. 5e and Supplementary Fig. 8). Therefore, miR-1269a directly targets Smad7 and HOXD10 through the identified binding sites in their 3′UTR.
HOXD10 has been reported to suppress tumour invasion and metastasis20. To test whether miR-1269a suppression of HOXD10 promotes invasion and metastasis, we transfected SW480 cells with vector constructs expressing both miR-1269a and HOXD10 mRNA without its 3′UTR (hence resistant to miR-1269a suppression). Transwell migration and Matrigel invasion assays revealed that ectopic expression of HOXD10 was able to abrogate miR-1269a-induced cell migration and invasion (Fig. 5f). We then ectopically expressed HOXD10 in SW620 cells and implanted the cells orthotopically into mouse cecum termini. Consistent with the in vitro migration and invasion assays, ectopic HOXD10 expression dramatically reduced hepatic metastasis in vivo (Fig. 5g,h).
miR-1269a and TGF-β forms a positive feedback loop
Smad7 is a well-known antagonist of TGF-β signalling21, although the effect of HOXD10 on TGF-β signalling is unclear. This raised the question as to whether miR-1269a regulates TGF-β signalling in CRC cells through its direct targets. Western blot showed that ectopic expression of miR-1269 in SW480 cells enhanced Smad2 phosphorylation. Consistently, Knockdown of miR-1269 target Smad7 or HOXD10 also promoted Smad2 phosphorylation (Fig. 6a). To evaluate the effect of HOXD10 and Smad7 on TGF-β targets gene expression, we established cell lines either expressing Smad7 or HOXD10, or containing a control vector. The cell lines were treated with TGF-β1 for 96 h before RT–qPCR and western blot were performed to measure TGF-β target genes, Slug, Snail and Sox4. As expected, TGF-β1 upregulated Slug, Snail and Sox4 expression in cell lines with the control vector. However, the upregulation was significantly reduced by ectopic expression of Smad7 or HOXD10 (Fig. 6b–e and Supplementary Fig. 9a–d), suggesting that HOXD10 is also an antagonist of TGF-β signalling in CRC cells. Ectopic expression of Smad7 or HOXD10 also reduced TGF-β induced miR-1269a upregulation, consistent with the fact that Sox4 levels are down (Fig. 6f and Supplementary Fig. 9e). Taken together, these data indicate that Smad7 and HOXD10 are antagonists of TGF-β signalling.
As miR-1269a directly targets Smad7 and HOXD10, both of which are antagonists of TGF-β signalling, we examined whether miR-1269a upregulates TGF-β signalling. As showed in Fig. 6g–i and Supplementary Fig. 9f–h, ectopic expression of miR-1269a increased the expression levels of all three target genes of TGF-β signalling, Slug, Snail and Sox4, in SW480 and HT29 cells. Slug, Snail and Sox4 are master regulators of EMT, and their expression in SW480 cells downregulated E-cadherin and upregulated N-cadherin (Fig. 6j). These data provide an explanation for the strong induction of EMT by miR-1269a in CRC cells—miR-1269a upregulates TGF-β signalling and its target genes, Slug, Snail and Sox4, via suppression of TGF-β antagonists Smad7 and HOXD10. To examine whether miR-1269a induces TGF-β expression, we performed RT–qPCR in SW480 cells that ectopically express miR-1269a. miR-1269a increased TGF-β1 expression, but had little effect on TGF-β2 and TGF-β3 expression (Supplementary Fig. 10). ELISA confirmed that miR-1269a also increased TGF-β1 protein level in SW480 medium (Fig. 6k). miR-1269a seems to upregulate TGF-β1 via a regulatory route independent of Smad7 and HOXD10, as knockdown of Smad7 and HOXD10 did not affect TGF-β1 level (Fig. 6i). Our studies suggest that TGF-β and miR-1269a form a positive feedback loop, wherein TGF-β upregulates miR-1269 via Sox4, whereas miR-1269 upregulates TGF-β1 and enhances TGF-β signalling by suppressing its antagonists Smad7 and HOXD10 (Fig. 7).
In this study, we performed differential analysis between early- and late-stage CRCs in TCGA to identify miR-1269 as a top candidate, which was confirmed by additional 29 CRC samples. A study of 100 stage II CRC patients revealed that miR-1269a expression level was associated with risk of relapse and metastasis. Mechanistically, this is because miR-1269a and TGF-β form a positive feedback loop via Sox4, HOXD10 and Smad7 to promote EMT and metastasis.
miR-1269a was a somewhat surprising candidate that emerged from our differential analysis because very little was known about this microRNA. A global study of eight paired samples of normal mucosa and CRC tumour reported that miR-1269 was one of the 16 microRNAs that were deregulated in tumour tissues22. Nevertheless, a differential expression analysis between normal and tumour tissues in TCGA did not suggest a statistically significant change in miR-1269a expression. Regardless, our analysis suggests that miR-1269a likely plays a more prominent role in CRC relapse and metastasis than in oncogenesis. Hence, the practice of grouping CRC tumours of various stages into a single group may mask the complexity of microRNA regulation during tumour progression.
miR-1269a does not promote metastasis alone; instead, it forms a positive feedback loop with TGF-β. This finding is consistent with the increasing appreciation that microRNAs form regulatory motifs with protein regulators to confer robustness to biological processes, and their subversion can expose cells to elevated risk of malfunction23. Therefore, the context is important for understanding the role of microRNAs in regulatory networks. For example, positive feedback is known to amplify a response and commits into a self-sustained mode that is autonomous to the original stimuli. It is tempting to speculate that, once induced by TGF-β, the miR-1269a-mediated feedback loop allows CRC cells to become more autonomous. This would enhance the ability of CRC cells to invade and metastasize to new microenvironments, which would explain the strong pro-metastasis phenotype we have observed.
Elevated TGF-β production is associated with high risk of CRC relapse and metastasis24. Stromal cells in the CRC microenvironment can also produce TGF-β, which increases the efficiency of organ colonization by CRC cells. In a likely scenario, TGF-β released from the microenvironment reaches a certain concentration to activate the positive feedback loop in CRC cells and promote their dissemination. Hence, miR-1269a may play an integrated role in the TGF-β-mediated crosstalk between CRC and stromal cells to confer a survival advantage to metastatic cells.
On the other hand, we certainly have to caution against over-simplification of CRC metastasis, which is a complicated process involving many players. In fact, our analysis indicates that, unlike miR-1269a, the association between TGF-β and relapse is not statistically significant among the 100 disease-free stage II CRC patients. This suggests that miR-1269a’s ability to promote recurrence and metastasis does not completely depend on its upregulation of TGF-β in tumour cells. Mutations could interfere with this feedback loop, whereas miR-1269a might also affect metastasis through other targets independent of TGF-β. Neither miR-1269a nor the positive feedback loop is likely to be sufficient or necessary for metastasis.
Human CRC cell lines SW480, SW620, HCT116, HT29, DLD1, LoVo and LS174T were acquired from American Type Culture Collection and cultured under the conditions recommended by the provider. For TGF-β activation, the cells were treated with 10 ng ml−1 TGF-β1 for 96 h, and TGF-β1 was replaced after 48 h.
Kaplan–Meier relapse analysis and clinical specimens
The studies followed informed consent and approval of the Ethical Committees at the Catalan Institute of Oncology and Weill Cornell Medical College. Tumour relapse was analysed by tracking 100 stage II CRC patients. The patients were divided into two groups, ‘miR-1269low’ and ‘miR-1269high’, based on the miR-1269 expression levels measured in their surgically removed primary tumours. microRNA expression was measured using Solid IV small-RNA sequencing and bowtie2 mapped to miRbase 20. Sample counts were normalized according to the library size using the DESeq bioconductor package (http://genomebiology.com/2010/11/10/r106). The cutoff threshold was set to separate the top 10% miR-1269high patients from the 90% ‘miR-1269low patients. The disease-free survival curves were estimated using the Kaplan–Meier method and compared with the log-rank test.
To evaluate miR-1269a expression in early- and late-stage CRC tumours, frozen CRC specimens were acquired from the WCMC Colon Cancer Biobank. Total RNA was then isolated from the frozen tissues using the Allprep DNA/RNA kit (Qiagen).
Quantitative real-time RT–PCR analysis
Total RNA was extracted from the cells using the TRIzol Reagent (Invitrogen). cDNA was synthesized from 500 ng of total RNA in 20 μl of reaction volume using the High Capacity cDNA Archive Kit (Applied Biosystems). miR-1269a and miR-1269b levels were measured by quantitative PCR using the TaqMan MicroRNA Assay (Applied Biosystems). Gene expression levels were measured by quantitative PCR using the SYBR Green System (Applied Biosystems). All samples were run in triplicates and were repeated three times. The respective miR-1269a and miR-1269b primers and U6 primer were purchased from Applied Biosystems. Other primer sequences include: HOXD10, 5′-GTGCAGGAGAAGGAAAGCAAAG-3′ and 5′-TAACGCTCTTACTGATCTCTAGGC-3′; Smad7, 5'-TGCTCCCATCCTGTGTGTTAAG-3' and 5′-TCAGCCTAGGATGGTACCTTGG-3′; Slug, 5′-CATGCCTGTCATACCACAAC-3′ and 5′-GGTGTCAGATGGAGGAGGG-3′; Snail, 5′-GAGGCGGTGGCAGACTAG-3′ and 5′-GACACATCGGTCAGACCAG-3′; Sox4, 5′-CACATCAAGCGACCCATGAAC-3′ and 5′-CCGGTACTTGTAGTCGGGGTAGT-3′; TGF-β1, 5′-CTCTCCGACCTGCCACAGA-3′ and 5′-AACCTAGATGGGCGCGATCT-3′; TGF-β2, 5′-CCGCCCACTTTCTACAGACCC-3′ and 5′-GCGCTGGGTGGGAGATGTTAA-3′; TGF-β3, 5′-CTGGCCCTGCTGAACTTTG-3′ and 5′-AAGGTGGTGCAAGTGGACAGA-3′; actin, 5′-CGCGAGAAGATGACCCAGAT-3′ and 5′-ACAGCCTGGATAGCAACGTACAT-3′. The expression of each gene was defined from the threshold cycle (Ct), and the relative expression levels were calculated using the 2-ΔΔCt method after normalization to the actin expression level.
Lentiviral vector constructs and infection
miR-1269a was ectopically expressed by the GFP hsa-miR-1269a Letivector and silenced by the inhibitor hsa-miR-1269a Letivector. These two vectors and the control vectors were ordered from Applied Biological Material. The Smad7 luciferase reporter, with the Smad7 3′UTR in the pMirtarget Vector, was ordered from OriGene. The HOXD10 luciferase reporter, pMIR-D10 UTR, was order from Addgene. miR-1269a-binding sequences in the Smad7 and HOXD10 luciferase reporters were mutated using the QuickChange Site-directed Mutagenesis Kit (Stratagene). To construct the reporter for miR-1269a promoter activity, the miR-1269a promoter sequence was amplified from human genomic DNA and cloned into the pGL4.10 vector (Promega). The putative Sox4-binding site in the miR-1269a promoter sequence was further mutated using the QuickChange Site-directed Mutagenesis Kit (Stratagene). Expression vectors for HOXD10, Smad7, Sox4, Slug and Snail (HOXD10-pcDNA, pBabe-puro-Smad7-HA, pWPXL-Sox4, pBabe-puro-Slug and pBabe-puro-Snail) were ordered from the Addgene. Short hairpin RNA constructs against HOXD10 and Smad7 were ordered from the Sigma. The reporter construct carrying luciferase and mCherry was order from the Addgene. The lentiviral vectors were co-transfected with helper plasmids into 293T cells. The retroviral vectors were transfected into phoenix cells. The viral supernatant was collected 48 h after transfection and was used to infect CRC cells.
Luciferase reporter assay
To validate the Sox4-binding sites in the miR-1269a promoter, miR-1269a promoter reporter construct with wide-type or mutated Sox4-binding sites was transfected with the pRL-SV40 Renilla luciferase vectors into SW480 and HT29 cells using the LT1 Transfection Reagent (Mirus). To validate whether HOXD10 and Smad7 are direct targets of miR-1269a, HOXD10 and Smad7 luciferase reporter constructs with wide-type or mutated miR-1269a-binding sites were transfected with the pRL-SV40 Renilla luciferase vector into SW480 and HT29 cells. 48 h after transfection, Luciferase assays were performed using the dual luciferase reporter assay system (Promega). Measurements from triplicate transfections were analysed after normalization to the Firefly luciferase activity.
Cells were grown on glass culture slides (BD Biosciences) and fixed with 4% cold methanol at −20 °C for 10 min. Subsequently, cells were blocked with 10% goat serum for 1 h and incubated with primary antibodies against E-cadherin (24E10, 1:200, Cell Signaling), N-cadherin (1:100, BD Biosciences) and Vimentin (D21H3, 1:100, Cell Signaling) at 4 °C for 1 h and then incubated with Rhodamine Red or Alexa Fluor 488-labelled secondary antibody (Invitrogen) for 1 h at room temperature. After counterstained with DAPI (Invitrogen), the slide was observed under a confocal microscope (Zeiss).
Chromatin immunoprecipitation assay
ChIP was performed using a ChIP assay kit (Millipore) according to the manufacturer’s instructions. Briefly, SW480 and HT29 cells either infected with a vector-expressing Sox4 or treated with TGF-β1 were incubated in 1% formaldehyde for 10 min at room temperature to crosslink their DNA. The cells were lysed in lysis buffer, sonicated to generate DNA fragments less than 500 base pairs in length and then diluted by tenfolds in ChIP Dilution Buffer. Before immunoprecipitation, nuclear extracts were pre-cleared with 50% protein G–Sepharose slurry, goat normal serum and sheared salmon sperm DNA for 2 h at 4 °C. Anti-Sox4 antibody (H-90, 1:50, Santa Cruz) was then added to form complexes with Sox4 protein and associated chromatin. These immunocomplexes were recovered by protein G–Sepharose beads, and the associated DNA was purified by extraction with phenol/chloroform. PCR Primers 5′-CAGTGGATTGAGTGAGGAAGATTCT-3′ and 5′-TGAGCCCCAGAGTCCAAGAG-3′ for site 1 and primers 5′-CCCTCACAGCAATTTTATAGCATCT-3′ and 5′-TCAAACAAATATGCCAGTCACTTCA-3′ were used to measure the enrichment of the putative Sox4-binding site in the miR-1269a promoter.
Whole-cell lysate was prepared in a lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS, protease inhibitors). Proteins were first separated by 10% SDS–PAGE and then transferred to a Hybond membrane (Amersham). The membranes were incubated with primary antibodies either anti-E-cadherin (24E10, 1:1000, Cell Signailing), anti-N-cadherin (1:1000, BD Biosciences), anti-HOXD10 (H-80, 1:1000, Santa Cruz), anti-Smad7 (B-8, 1:500, Santa Cruz), anti-Snail (C15D3, 1:1000, Cell Signaling), anti-Slug (C19G7, 1:1000, Cell Signaling), anti-Sox4 (C20, 1:100, Santa Cruz), anti-Phospho-Smad2 (1:1000, Cell Signaling) or anti-β-actin (13E5, 1:1000, Cell Signaling) in 5% milk/TBST buffer (25 mM Tris pH 7.4, 150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight, and then probed for 1 h with secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Santa Cruz). After extensive wash with PBST, the target proteins were detected on membrane by enhanced chemiluminescence (Pierce). Full scans of western blots are included in Supplementary Figs11 and 12.
Analysis of Proliferation, migration and invasion
SW480 cells were infected with either the control or miR-1269a expression lentiviral vectors. The infection efficiency was measured by GFP expression from the vectors. Cell proliferation under differentiating condition was analysed using the WST-1 Cell Proliferation Reagent (Clontech). Migration assay and invasion assay were performed as previously described. Briefly, 1 × 105 cells were plated in the serum-free medium in the upper chamber with the non-coated membrane (24-well insert; pore size, 8 mm; BD Biosciences) for migration assay and with Matrigel-coated membrane (24-well insert; pore size, 8 mm; BD Biosciences) for invasion assay. The lower chamber was filled with medium containing 20% fetal bovine serum. The cells were incubated for 24 h at 37 °C. The cells did not traversed the membrane were removed by a cotton swab and the cells on the lower surface of the membrane were stained with crystal violet and observed under a microscope.
In vivo experiments
All animal experiments were approved by the Cornell Center for Animal Resources and Education and followed the protocol (2009-0071 and 2010-0100).
For subcutaneous injection, 8 × 106 cancer cells were injected into the lower back region of 5-week-old female nude mice, with five mice per group. The mice were killed and the tumours were collected and weighed when one of the mice had developed severe tumour burden.
For intravenous injection, 2 × 106 cancer cells were injected into 5-week-old female NOD/SCID mice, with ten mice per group. The mice were killed and lung/liver metastasis was evaluated when one of them became moribund.
For cecum injection, cells were carrying a reporter construct expressing luciferase and mCherry. After FACS sorting, 4 × 106 cells were injected into 5-week-old female NOD/SCID mice, with eight mice per group. After injection, luciferase signal was tracked in vivo using the IVIS luciferase imaging system 200 (Xenogen). When one of the mice became moribund, all mice were killed and liver metastases were evaluated based on mCherry signals by an OV100 microscope (Olympus).
Lung and liver tissues from mice injected with CRC cells with miR-1269a expression or silencing vectors were removed and fixed in 4% paraformaldehyde overnight. Paraffin-embedded sections were processed for H&E staining.
microRNA expression profiles of CRC tumours at different stages were compared by analysing miRNASeq data from the TCGA COAD data set. A total of 409 samples were grouped according to the AJCC tumour-node-metastasis staging. Stage I (68 samples) and Stage II (162 samples) CRCs were combined to form the early-stage CRC cohort, which was compared with stage IV samples (59 samples) as the late-stage cohort. DESeq was used for differential analysis of the microRNA expression profiling between early- (stage I and II) and late-stage (stage IV) CRC cohorts.
Data were expressed as mean±standard deviation of no smaller than three biological repeats, unless otherwise noted. Student’s t-tests were used for comparisons, with P<0.05 considered significant. Survival curves were estimated using the Kaplan–Meier method and compared using the logrank test. The multivariate analysis was performed with a Cox’s proportional hazards model. Hazard ratios and 95% confidence intervals were derived from the model and the likelihood ratio test was used to compare the groups.
How to cite this article: Bu, P. et al. miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. Nat. Commun. 6:6879 doi: 10.1038/ncomms7879 (2015).
Yokota, J. Tumor progression and metastasis. Carcinogenesis 21, 497–503 (2000).
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nature Med. 19, 1423–1437 (2013).
Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220–241 (2012).
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).
Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275–292 (2011).
Benson, A. B. 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22, 3408–3419 (2004).
Chun, P. & Wainberg, Z. A. Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest. Cancer Res. 3, 191–196 (2009).
Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704–714 (2009).
Kasinski, A. L. & Slack, F. J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849–864 (2011).
Valeri, N. et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25, 469–483 (2014).
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Colonomics.org http://bioinfo.iconcologia.net/colonomics/ (2014).
Leibovitz, A. et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36, 4562–4569 (1976).
Fu, X. Y., Besterman, J. M., Monosov, A. & Hoffman, R. M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc. Natl Acad. Sci. USA 88, 9345–9349 (1991).
Cespedes, M. V. et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am. J. Pathol. 170, 1077–1085 (2007).
Brabletz, T. et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179, 56–65 (2005).
Kuwahara, M. et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat. Immunol. 13, 778–786 (2012).
Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768–783 (2013).
Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682–688 (2007).
Yan, X., Liu, Z. & Chen, Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim. Biophys. Sin. (Shanghai) 41, 263–272 (2009).
Hamfjord, J. et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One 7, e34150 (2012).
Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515–524 (2012).
Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571–584 (2012).
We thank Robert Weiss and members of the Shen laboratories for discussions. We also thank the investigators and institutions of the TCGA research network that have contributed to the TCGA data used for this study. This work was supported by NIH R01GM95990, NSF 1350659 career award, NSF 1137269, DARPA 19-1091726, Instituto de Salud Carlos III grant PI11-01439, CIBERESP CB07/02/2005, the Spanish Association Against Cancer (AECC) Scientific Foundation, the Catalan Government DURSI grant 2009SGR1489 and the European Commission FP7-COOP-Health-2007-B HiPerDART.
The authors declare no competing financial interests.
About this article
Cite this article
Bu, P., Wang, L., Chen, KY. et al. miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. Nat Commun 6, 6879 (2015). https://doi.org/10.1038/ncomms7879
Signatures of genetic variation in human microRNAs point to processes of positive selection and population-specific disease risks
Human Genetics (2022)
Cell Death Discovery (2021)
LncRNA LINC00261 overexpression suppresses the growth and metastasis of lung cancer via regulating miR-1269a/FOXO1 axis
Cancer Cell International (2020)
Common and Unique microRNAs in Multiple Carcinomas Regulate Similar Network of Pathways to Mediate Cancer Progression
Scientific Reports (2020)